Parker Waichman LLP Comments on FDA's Recent Requirement to Add a Black Box Warning Indicating Increased Risk of Death to Patients using Gout Prescription Medication Uloric
Parker Waichman LLP Reports that FDA Analysis Shows Increased Risk of Death While Taking Uloric
PORT WASHINGTON, N.Y., Feb. 27, 2019 /PRNewswire/ -- On February 21, 2019, the U.S. Food and Drug Administration (FDA) announced that the results of their analysis from a review of a safety trial conclude that adults who take Uloric (febuxostat) to combat the symptoms of gout are at an elevated risk of suffering from cardiovascular complications and other causes leading to death when compared to another gout medication, Allopurinol. As a consequence of these findings, the FDA declared that it would take two remedial measures to inform physicians and patients of the increased threat presented by Uloric (febuxostat). The FDA will require Uloric (febuxostat) to include a Boxed Warning on its label calling attention to the increased chance of death from taking the medication and provide patients with a new Medication Guide. Secondly, the FDA will limit the authorized use of Uloric (febuxostat) to cases in which the patient has experienced severe side effects after taking Allopurinol.
Parker Waichman LLP is Reviewing Injury and Death Claims Involving Uloric
Parker Waichman LLP is currently reviewing cases involving injuries or wrongful death of individuals who took Uloric and suffered heart attack, stroke, unstable angina or death. According to the FDA, gout is the result of the accumulation of uric acid in the joints. Patients most commonly experience redness, excessive swelling, and pain when they suffer a gout attack. Parker Waichman LLP Senior Partner Jerrold S. Parker stated, "The severity of the injuries and risks associated with Uloric has been released to the public and demands justice for those who have been wrongly affected and now must struggle with serious health issues and diminished quality of life."
Filing a Claim for Compensation for Illness or Death Resulting from Use of Uloric
Parker Waichman LLP represents injury victims and the families of those harmed by the prescription drug Uloric and has recovered more than $2 billion in damages for its clients. If you or a family member have suffered complication with Uloric and are interested in filing a Uloric (febuxostat) lawsuit, contact Parker Waichman LLP at the firm's website at yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636) or visit our website at www.yourlawyer.com.
CONTACT: Raymond C. Silverman 516-466-6500
Related Links
https://www.fda.gov/Drugs/DrugSafety/ucm631182.htm
SOURCE Parker Waichman LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article